As of June 13, 2025, Acer Therapeutics Inc (ACER) reports a Net Margin of -1220.16%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Acer Therapeutics Inc's Net Margin
Over recent years, Acer Therapeutics Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2022-12-31 | -1220.16% |
| 2021-12-31 | -1220.16% |
| 2020-12-31 | -274.23% |
| 2019-12-31 | -469.53% |
| 2018-12-31 | -1185.04% |
This slight upward trend highlights how Acer Therapeutics Inc manages its overall profitability and cost control over time.
Comparing Acer Therapeutics Inc's Net Margin to Peers
To better understand Acer Therapeutics Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Acer Therapeutics Inc (ACER) | -1220.16% |
| Royalty Pharma PLC (RPRX) | 37.95% |
| Zoetis Inc (ZTS) | 26.86% |
| Merck & Co Inc (MRK) | 26.68% |
| Eli Lilly and Co (LLY) | 23.51% |
| Johnson & Johnson (JNJ) | 15.84% |
Compared to its competitors, Acer Therapeutics Inc's Net Margin is among the lowest compared to peers, which may indicate challenges in controlling expenses or competitive pricing pressures.